← Oncology Approval Tracker

FDA DECISION ·

Pemetrexed Injection (Actavis) + pembrolizumab and platinum

pemetrexed plus pembrolizumab and platinum chemotherapy · Actavis

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Initial treatment with pembrolizumab and platinum chemotherapy in metastatic nonsquamous NSCLC without EGFR or ALK genomic aberrations, using the specified pemetrexed product.

LAMPGEN ANALYSIS

Why it matters

The decision adds the immunochemotherapy combination to this product’s labeled use.

What research teams should watch

Verify genomic testing and product-level labeling when reconciling the regimen in pharmacy.

PRIMARY RECORDS

Sources